Assertio Holdings, INC 10-Q quarterly reports

Assertio Holdings reported a net loss of $18.9 million for Q1 2026 while finalizing a $21.80 per share acquisition agreement with Garda Therapeutics.

Assertio Holdings, Inc. reported a net income of $11.4 million for Q3 2025, driven by strong ROLVEDON sales, but anticipates no material ROLVEDON sales in the next two quarters due to integration efforts.

Assertio Holdings, Inc. reported a significantly wider net loss for the second quarter and first half of 2025, driven by strategic divestitures and ongoing legal expenses, despite some product sales growth.

Assertio Holdings' Q1 2025 results reveal a revenue decrease due to generic competition and pricing pressures, alongside a strategic divestiture of Assertio Therapeutics to streamline operations.

Assertio Holdings experienced a decrease in overall revenue for the third quarter of 2024, primarily due to generic competition impacting legacy products, while ROLVEDON sales showed growth.

Assertio Holdings' second quarter results show a net loss, impacted by generic competition for INDOCIN, while ROLVEDON sales continue to grow.

Assertio Holdings experienced a revenue decrease in the first quarter of 2024, primarily due to generic competition impacting sales of its INDOCIN products, despite growth in ROLVEDON sales.